医药行业周报：ARS吸入式过敏疗法Neffy获FDA批准

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index within the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.96% on March 7, 2025, underperforming the CSI 300 index by 0.65 percentage points, ranking 22nd among 31 sub-industries [4]. - The approval of ARS's Neffy (1 mg epinephrine nasal spray) by the FDA marks a significant innovation in the delivery method for treating type I allergic reactions in children aged 4 and above, representing the first major advancement in 35 years for this patient group [5]. - Notable stock performances included Aosaikang (+9.99%), Yipinhong (+9.77%), and Rejing Biology (+8.84%) on the gainers' list, while Aopumai (-6.26%), Puri Eye (-5.97%), and BGI (-4.86%) led the decliners [4]. Summary by Sections Market Performance - As of March 7, 2025, the pharmaceutical sector's performance was -0.96%, with sub-sectors like in vitro diagnostics (-0.43%) and blood products (-0.72%) performing better, while hospitals (-2.11%) and medical devices (-1.67%) lagged [4]. Industry News - ARS announced FDA approval for Neffy, a nasal spray for treating severe allergic reactions in children, highlighting a significant advancement in treatment options [5]. - Jingxin Pharmaceutical announced an increase in its share buyback plan from a minimum of RMB 200 million to RMB 350 million, with a maximum limit raised from RMB 400 million to RMB 700 million [5]. - Novogene signed a strategic cooperation agreement with BGI to collaborate on various health management areas [5]. Company News - Heng Rui Pharmaceutical received clinical trial approval for several new drugs, indicating ongoing development in their pipeline [6]. - Kanglong Chemical reported the completion of a share reduction plan, with a total of 10,666,716 shares sold, representing 0.60% of the company's total equity [6].